Literature DB >> 22842721

Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer.

Nadia Howlader1, Anne-Michelle Noone, Mandi Yu, Kathleen A Cronin.   

Abstract

The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program provides a rich source of data stratified according to tumor biomarkers that play an important role in cancer surveillance research. These data are useful for analyzing trends in cancer incidence and survival. These tumor markers, however, are often prone to missing observations. To address the problem of missing data, the authors employed sequential regression multivariate imputation for breast cancer variables, with a particular focus on estrogen receptor status, using data from 13 SEER registries covering the period 1992-2007. In this paper, they present an approach to accounting for missing information through the creation of imputed data sets that can be analyzed using existing software (e.g., SEER*Stat) developed for analyzing cancer registry data. Bias in age-adjusted trends in female breast cancer incidence is shown graphically before and after imputation of estrogen receptor status, stratified by age and race. The imputed data set will be made available in SEER*Stat (http://seer.cancer.gov/analysis/index.html) to facilitate accurate estimation of breast cancer incidence trends. To ensure that the imputed data set is used correctly, the authors provide detailed, step-by-step instructions for conducting analyses. This is the first time that a nationally representative, population-based cancer registry data set has been imputed and made available to researchers for conducting a variety of analyses of breast cancer incidence trends.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842721      PMCID: PMC3491971          DOI: 10.1093/aje/kwr512

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  15 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

Review 2.  Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project.

Authors:  Nancy Krieger; Jarvis T Chen; Pamela D Waterman; Mah-Jabeen Soobader; S V Subramanian; Rosa Carson
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

3.  Racial differences in breast cancer trends in the United States (2000-2004).

Authors:  Ruth M Pfeiffer; Aya Mitani; Rayna K Matsuno; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

4.  Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries.

Authors:  Marsha E Reichman; Sean Altekruse; Christopher I Li; Vivien W Chen; Dennis Deapen; Mary Potts; Xiao-Cheng Wu; Donna Morrell; Jennifer Hafterson; Amanda I Phipps; Linda C Harlan; Lynn G Ries; Brenda K Edwards
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

Review 5.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

6.  Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions.

Authors:  Nancy Krieger; Jarvis T Chen; James H Ware; Afamia Kaddour
Journal:  Cancer Causes Control       Date:  2008-08-14       Impact factor: 2.506

7.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Authors:  Andrew G Glass; James V Lacey; J Daniel Carreon; Robert N Hoover
Journal:  J Natl Cancer Inst       Date:  2007-07-24       Impact factor: 13.506

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

10.  Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.

Authors:  Ahmedin Jemal; Elizabeth Ward; Michael J Thun
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  33 in total

1.  Use of multiple imputation to correct for bias in lung cancer incidence trends by histologic subtype.

Authors:  Mandi Yu; Eric J Feuer; Kathleen A Cronin; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-22       Impact factor: 4.254

2.  Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGFI receptor.

Authors:  Jennifer A Emond; John P Pierce; Loki Natarajan; Laarni R Gapuz; John Nguyen; Barbara A Parker; Nissi M Varki; Ruth E Patterson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-22       Impact factor: 4.254

3.  Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.

Authors:  Philip S Rosenberg; Kimberly A Barker; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

Review 4.  GIScience and cancer: State of the art and trends for cancer surveillance and epidemiology.

Authors:  Liora Sahar; Stephanie L Foster; Recinda L Sherman; Kevin A Henry; Daniel W Goldberg; David G Stinchcomb; Joseph E Bauer
Journal:  Cancer       Date:  2019-05-30       Impact factor: 6.860

5.  Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Authors:  Salomon Manier; Daisy Huynh; Yu J Shen; Jia Zhou; Timur Yusufzai; Karma Z Salem; Richard Y Ebright; Jiantao Shi; Jihye Park; Siobhan V Glavey; William G Devine; Chia-Jen Liu; Xavier Leleu; Bruno Quesnel; Catherine Roche-Lestienne; John K Snyder; Lauren E Brown; Nathanael Gray; James Bradner; Luke Whitesell; John A Porco; Irene M Ghobrial
Journal:  Sci Transl Med       Date:  2017-05-10       Impact factor: 17.956

6.  [Clinical features of neuroblastoma: an analysis of 44 children].

Authors:  Cheng-Guang Zhu; Xiang-Ling He; Zhi-Ge Tang; Ke-Ke Chen; Run-Ying Zou; Xin Tian; Ya-Lan You
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-11

7.  Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.

Authors:  William F Anderson; Philip S Rosenberg; Hormuzd A Katki
Journal:  J Natl Cancer Inst       Date:  2014-04-28       Impact factor: 13.506

8.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

Authors:  Nadia Howlader; Sean F Altekruse; Christopher I Li; Vivien W Chen; Christina A Clarke; Lynn A G Ries; Kathleen A Cronin
Journal:  J Natl Cancer Inst       Date:  2014-04-28       Impact factor: 13.506

9.  Optimization of harvesting, extraction, and analytical protocols for UPLC-ESI-MS-based metabolomic analysis of adherent mammalian cancer cells.

Authors:  Huichang Bi; Kristopher W Krausz; Soumen K Manna; Fei Li; Caroline H Johnson; Frank J Gonzalez
Journal:  Anal Bioanal Chem       Date:  2013-04-19       Impact factor: 4.142

10.  Gamma knife radiosurgery for management of cerebral metastases from esophageal carcinoma.

Authors:  Greg Bowden; Hideyuki Kano; Zachary J Tempel; Ellen Caparosa; Edward Monaco; Ajay Niranjan; John Flickinger; James D Luketich; L Dade Lunsford
Journal:  J Neurooncol       Date:  2014-04-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.